Last checked at 31 Mar 2014 16:46
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director Resignation
As announced on 20 March 2014, EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, confirms today that Mr Gordon James Hall, a non-executive Director, has stepped down from the Board with immediate effect. The Board wish to thank Mr Hall for his excellent contribution and continue to seek a senior Non-Executive Director to replace Mr Hall.
Enquiries:
EKF Diagnostics Holdings plc | Tel: 029 2071 0570 | ||
David Evans, Executive Chairman | Mob: 07740 084 452 | ||
Julian Baines, CEO | Mob: 07788 420 859 | ||
Paul Foulger, CFO | Mob:07710 989 255 | ||
|
| ||
Canaccord Genuity Limited
Nominated Adviser/Corporate Broking | Tel: 020 7523 8000 | ||
Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors |
|
| |
|
| ||
Walbrook PR Limited | Tel: 020 7933 8780 | ||
Paul McManus | Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com | ||
Paul Cornelius | Mob: 07866 384 707 or paul.cornelius@walbrookir.com | ||
About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.